Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weigh loss, are placed on a table for a photograph in a health clinic in Hyderabad, India, April 14, 2025.
Credit: Reuters File Photo
- Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for Rs 14,000 (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk.
Lilly said in June it received approval from India’s drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device.
Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply.
The smallest two doses are priced at Rs 14,000 and Rs 17,500, respectively, and the 7.5 mg and 10 mg doses cost Rs 22,000. The 12.5 mg and 15 mg doses cost Rs 27,500, the company said.
"If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive," said Vishal Manchanda from Systematix Institutional Equities.
Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost Rs 17,345 a month, and its highest doses of 1.7 mg and 2.4 mg cost Rs 24,280 and Rs 26,015 a month, respectively.
Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month.
The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.